Delayed diagnosis of the neuromyelitis optica spectrum disorder

Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory demyelinating diseases of the central nervous system. In 2015, International Expert Panel established diagnostic criteria for NMOSD. The majority of patients with NMOSD have aquaporin-4 autoantibody (AQP4-IgG). This case describes a 43-year-old woman who presented with weakness in her limbs followed by intractable vomiting. One year and 3 months later, she experienced acute visual impairment, which recurred several times. MRI of the spinal cord revealed a T2-hyperintense signal lesion at the cervical level extending over 4 vertebral segments. MRI of the brain showed involvement of the brainstem. AQP4-IgG was detected in her blood serum. It took 30 months from the onset of symptoms to establish the correct diagnosis. During this time, several incorrect diagnoses were made, including ischemic stroke, functional movement disorder and vertebrobasilar insufficiency. As a result of delayed diagnosis and treatment, the patient developed severe irreversible visual impairment. This case underscores the importance of early diagnosis and early treatment of NMOSD.

1. Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi: 10.3389/fneur.2020.00501

2. Papp V, Magyari M, Aktas O, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2021 Jan 12;96(2):59-77. doi: 10.1212/WNL.0000000000011153

3. Pandit L, Asgari N, Apiwattanakul M, et al; GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler. 2015 Jun;21(7):845-53. doi: 10.1177/1352458515572406

4. Wingerchuk DM, Banwell B, Bennett JL, et al. International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. 2015;85:177-89. doi: 10.1212/WNL.0000000000001729

5. Deguchi S, Deguchi K, Sato K, et al. HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med. 2012;51(18):2617-20. doi: 10.2169/internalmedicine.51.7898. Epub 2012 Sep 15.

6. Yang B, Guo L, Yang X, Yu N. The pathogenesis and treatment of posterior reversible encephalopathy syndrome after neuromyelitis optica spectrum disorder: a case report and literature review. BMC Neurol. 2022 Dec 20;22(1):493. doi: 10.1186/s12883-022-02985-8

7. Kim HJ, Paul F, Lana-Peixoto MA, et al.; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18.

8. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012 Feb 28;78(9):665-71; discussion 669. doi: 10.1212/WNL.0b013e318248dec1

9. Sherman MA, Boyko AN. Epidemiology of neuromyelitis optica spectrum disorder. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(7-2):5-12. doi: 10.17116/jnevro20211210725 (In Russ.).

10. Sherman E, Han MH. Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder. Curr Treat Options Neurol. 2015 Nov;17(11):48. doi: 10.1007/s11940-015-0378-x

11. Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346-51. doi: 10.1136/jnnp-2017-316286

12. Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021 Jan;20(1):60-7. doi: 10.1016/S1474-4422(20)30392-6

13. Belova AN, Bojko AN, Belova EM. Diagnostic criteria for neuromyelitis optica spectrum disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(2-2):32-40. doi: 10.17116/jnevro20161162232-40 (In Russ.).

14. Gomes ABAGR, Adoni T. Differential diagnosis of demyelinating diseases: what's new? Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):137-42. doi: 10.1590/0004-282X-ANP-2022-S109

15. Krasnov VS, Bakhtiyarova KZ, Evdoshenko EP, et al. Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):139-48. 10.14412/2074-2711-2022-6-139-148 (In Russ.).

16. Boyko AN. Comments on the article “Consensus opinion on the management of patients with neuromyelitisoptica spectrum diseases: issues of terminology and therapy”. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(1):119-22. doi: 10.14412/2074-2711-2023-1-119-122 (In Russ.).

17. Waters P, Pittock SJ, Bennett JL, et al. Evaluation of aquaporine-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290-303. doi: 10.1111/cen3.12107

18. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1-16. doi: 10.1007/s00415-013-7169-7

19. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18(1):5-10. doi: 10.1177/1352458511431077

20. Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017 Sep;264(9):2003-9. doi: 10.1007/s00415-017-8590-0. Epub 2017 Aug 22.

21. Songwisit S, Kosiyakul P, Jitprapaikulsan J, et al. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020 Oct 7;10(1):16727. doi: 10.1038/s41598-020-73882-8

22. Pittock SJ, Fujihara K, Palace J, et al. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler J. 2022;28(3):480-6. doi: 10.1177/13524585211038291

23. Velasco M, Zarco LA, Agudelo-Arrieta M. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. Mult Scler Relat Disord. 2021 May;50:102869. doi: 10.1016/j.msard.2021.102869

24. Nie T, Blair HA. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder. CNS Drugs. 2022;36:1133-41. doi: 10.1007/s40263-022-00949-7

25. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023. doi: 10.1002/ana.26626. Epub 2023 Mar 3.